Regorafenib-<wbr/><sup>13</sup>C-d<sub>3</sub>

Regorafenib-13C-d3

CAT N°: 25486
Price:

365.00 310.25

Regorafenib-13C-d3 is intended for use as an internal standard for the quantification of regorafenib (Item No. 18498) by GC- or LC-MS. Regorafenib is an orally bioavailable multi-kinase inhibitor with anticancer activity.{29730} It inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFR? with IC50 values of 1.5, 2.5, 4.2, 7, 13, and 22 nM, respectively. Regorafenib also inhibits B-RAF, VEGFR3, FGFR, and Tie2 (IC50s = 28, 46, 202, and 311 nM, respectively) as well as other kinases.{29730,27528,29728} In vivo, regorafenib (10 mg/kg) reduces tumor size in the MDA-MB-231 breast and 786-O renal cancer mouse xenograft models.{29730} It also reduces tumor microvessel area and inhibits tumor growth in a panel of mouse xenograft models. Formulations containing regorafenib have been used in the treatment of advanced gastrointestinal stromal tumors and metastatic colorectal cancer.

We also advise you

TAF 10 Peptide

TAF 10 Peptide

TAF10 is one of many protein factors or coactivators associated with RNA polymerase II activity.{16903} One vial of this peptide...

€191.00
View